Department of Dermatology and Allergology, University Medical Center, Munich, Germany.
Department of Ophthalmology at Mathildenstraße, University Medical Center, Munich, Germany.
J Dtsch Dermatol Ges. 2019 May;17(5):488-491. doi: 10.1111/ddg.13809. Epub 2019 Mar 15.
Since September 2017, the monoclonal antibody dupilumab (Dupixent ) has been approved in the EU for the treatment of moderate-to-severe atopic dermatitis. By blocking IL-4 and IL-13 signaling pathways, dupilumab improves both objective signs and subjective symptoms of the disease. Blocking of the IL-4aRα subunit leads to improvement of the skin's barrier function and reduction in Th2-mediated inflammation. While the rate of adverse events on dupilumab is generally low, mild-to-moderate conjunctivitis associated with redness as well as a burning and foreign body sensation has been reported in up to 28 % of patients. Treatment options include topical corticosteroids and topical calcineurin inhibitors. The present review highlights the clinical presentation of dupilumab-associated conjunctivitis and addresses pharmacological and non-pharmacological options available for the treatment of this clinically highly relevant condition.
自 2017 年 9 月以来，单克隆抗体度普利尤单抗（Dupixent）已在欧盟获批用于治疗中重度特应性皮炎。通过阻断 IL-4 和 IL-13 信号通路，度普利尤单抗改善了疾病的客观体征和主观症状。阻断 IL-4aRα 亚单位可改善皮肤屏障功能并减少 Th2 介导的炎症。虽然度普利尤单抗的不良反应发生率通常较低，但高达 28%的患者报告出现与发红、烧灼感和异物感相关的轻度至中度结膜炎。治疗选择包括局部皮质类固醇和局部钙调神经磷酸酶抑制剂。本综述重点介绍了与度普利尤单抗相关的结膜炎的临床表现，并讨论了治疗这种具有重要临床意义的疾病的药理学和非药理学选择。
